Isomorphic Labs

An Alphabet-owned drug discovery company that commercializes protein structure prediction technology developed by Google DeepMind. - Released proprietary IsoDDE model in February 2026; partnerships with major pharmaceutical companies

Determining the three-dimensional shape of a single protein used to take a graduate student an entire career. In March 2026, Google DeepMind released AlphaFold 4, a system that predicts the structure of multi-protein complexes in minutes rather than hours or days, extending a streak of capability gains that began when the original AlphaFold won a protein-prediction competition in 2018. Weeks earlier, DeepMind's drug-discovery spinoff Isomorphic Labs disclosed a proprietary model called IsoDDE that more than doubles AlphaFold 3's accuracy on key drug-design benchmarks, while a team at the National University of Singapore published D-I-TASSER, a tool that outperforms both AlphaFold 2 and AlphaFold 3 on difficult multi-domain proteins.

Updated 2 hours ago

DeepMind spin-out using AI for drug discovery, backed by $3 billion in pharma partnerships. - First clinical trials expected late 2026

Science magazine named large language models doing frontier science a runner-up breakthrough of 2025. Within weeks, the prediction became reality: OpenAI's GPT-5.2 solved previously unsolved Erdős mathematics problems in 15 minutes, achieving 40% accuracy on expert-level mathematics that stumped earlier systems. DeepMind announced its first automated laboratory in the UK for 2026, pairing Gemini with robotics to synthesize hundreds of materials daily. Google partnered with the U.S. Department of Energy on Genesis, a national AI-for-science platform mobilizing 17 national laboratories.

Updated Jan 22